Evonik's Lipid Milestone and a 40% Earnings Leap Sit Behind Jefferies' Cautious Re-Rating
Published on 11/14/2026 at 13:51 | Editorial boerse-global.de
Jefferies has nudged its price target on Evonik higher even as it stepped back from its buy recommendation, lifting the objective from 20 to 21 euros while cutting the stock to hold. The move, circulated on Tuesday, pairs a brighter valuation marker with a gloomier profit outlook — a combination that captures the tug-of-war now surrounding the specialty chemicals maker.
At the heart of the downgrade is a softer medium-term earnings picture. The brokerage trimmed its 2027 forecast for adjusted EBITDA by 9%, leaving the estimate below the 2 billion euro mark. Its reasoning leans on fading tailwinds: the profit boost Evonik has enjoyed from supply disruptions in the Middle East is expected to lose force. Over the near term, Jefferies argues, potential talks with BASF will matter more to the share price than the underlying fundamentals.
A Takeover Overture That Won't Go Away
That M&A thread remains live. BASF has put 24.00 euros per Evonik share on the table, and the two companies' chief executives and finance chiefs have already met in person. Evonik used that first exchange to restate its commitment to going it alone, according to Reuters, which reported the stance on Monday; the Handelsblatt said the group reaffirmed its desire for independence at the sit-down.
No concrete takeover negotiations were in sight, the Handelsblatt added. dpa-AFX, citing sources, reported the same day that no deal talks were underway between the two firms. No further meetings had been scheduled, meaning the additional conversations Jefferies flags as a potential share-price catalyst are not confirmed.
Should investors sell immediately? Or is it worth buying Evonik?
The Operating Engine Is Still Humming
Against that backdrop, Evonik's recent trading has been robust. On 3 November the company reported third-quarter 2026 adjusted EBITDA of 629 million euros, a 40% jump on the same period a year earlier. Management also sharpened its full-year 2026 guidance to the upper half of its existing range of 2.0 to 2.2 billion euros for adjusted EBITDA — a signal that the momentum is expected to carry through the year.
There was a portfolio note alongside the numbers: a buyer for Oxeno is anticipated in the coming months.
First GMP Batch Rolls Off the Line in Indiana
Evonik also flagged manufacturing progress on Tuesday from Lafayette, Indiana, where its new Lipid Innovation Center produced its first GMP-compliant batch of pharmaceutical lipids. The US government backed the facility, and full production capacity is targeted for the middle of 2027.
Evonik at a turning point? This analysis reveals what investors need to know now.
Investors will get their next full look under the hood on 4 March 2027, when Evonik publishes its annual report — including fourth-quarter and full-year 2026 results.
Ad
Evonik Stock: New Analysis - 14 November
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
